Innovation in Pediatric Drugs Act of 2025
SB 705, the Innovation in Pediatric Drugs Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act and related health laws to change how pediatric study requirements are enforced for drugs and biological products. The bill focuses on the Pediatric Research Equity Act framework, including noncompliance notices, due-diligence review, enforcement limits for products no longer marketed, and a delayed effective date for new enforcement authority. It also requires FDA reporting on penalties, settlements, and compliance with pediatric study deadlines.
The bill further addresses pediatric studies for orphan drugs and rare diseases. It would generally exempt orphan-designated products from pediatric study requirements unless FDA determines the studies could provide meaningful therapeutic benefit, while directing FDA to issue guidance, hold a public meeting, and maintain waiver lists for adult-related diseases and conditions. The measure also preserves existing requirements for molecularly targeted pediatric cancer investigations, authorizes NIH to devote up to 1 percent of pediatric research funds to pediatric drug studies for fiscal years 2026 through 2030, and requires a GAO study on the impact of these changes on rare disease drug development and pediatric labeling information.
If enacted, the bill would modify several provisions of the FDCA, especially section 505B governing pediatric study requirements, and would also amend FDA reporting obligations and enforcement procedures. It would create new statutory limits and process requirements for FDA enforcement, add transparency around penalties and settlements, and establish a transition period before enforcement can begin. The bill would also affect orphan drug sponsors, pediatric drug developers, FDA’s guidance and waiver practices, NIH pediatric research funding, and GAO oversight of rare disease and pediatric drug policy.
The available context shows the bill was introduced and referred to the Senate Committee on Health, Education, Labor, and Pensions, with no recorded votes or committee transcript excerpts provided. Based on the text, the measure appears generally supportive of pediatric drug development and rare disease research while also seeking to make FDA enforcement more structured and transparent. The overall tone of the legislation is reform-oriented rather than punitive, with an emphasis on clarity, due process, and balancing pediatric evidence generation against rare disease development challenges.
The main points of potential contention are the bill’s treatment of orphan drugs and the scope of FDA enforcement. Supporters are likely to favor the added flexibility for rare disease and orphan-drug sponsors, the waiver framework, and the requirement for guidance and public input. Critics may be concerned that narrowing pediatric study obligations for orphan-designated products could reduce pediatric data collection, while others may question the bill’s limits on enforcement against noncompliant sponsors or the practical effect of automatic waiver lists. The bill explicitly preserves molecularly targeted pediatric cancer investigations, suggesting that any debate over exemptions is intended to stop short of weakening those cancer-specific requirements.